Vasculitis
MONDO:0018882Vasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant-cell arteritis and Takayasu arteritis), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behcet disease) to relatively minor skin disease.
Also known as: systemic vasculitis, angiitis
286 clinical trials for this condition and its sub-types, 63 tagged with Vasculitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vasculitis
-
Necrotizing vasculitis 0 trials · 143 incl. sub-types
3 sub-types
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 82 trials · 130 incl. sub-types Sub-types →
- Immunoglobulin A vasculitis 16 trials
- Disseminated visceral giant cell angiitis 0 trials
-
Arteritis 5 trials · 104 incl. sub-types
7 sub-types
- Granulomatous angiitis 0 trials · 52 incl. sub-types Sub-types →
- Microscopic polyangiitis 34 trials
- Takayasu arteritis 27 trials
- Polyarteritis nodosa 7 trials · 9 incl. sub-types Sub-types →
- Cerebral arteritis 0 trials
- Endarteritis 0 trials
- Juvenile temporal arteritis 0 trials
-
Central nervous system vasculitis 3 trials · 55 incl. sub-types
5 sub-types
- Temporal arteritis 52 trials Sub-types →
- Primary central nervous system vasculitis 2 trials Sub-types →
- Benign angiitis of the central nervous system 0 trials
- Central nervous system AIDS arteritis 0 trials
- Cerebral arteritis 0 trials
-
Phlebitis 13 trials · 21 incl. sub-types
1 sub-type
- Thrombophlebitis 6 trials · 9 incl. sub-types Sub-types →
-
Immune complex mediated vasculitis 0 trials · 18 incl. sub-types
5 sub-types
- Immunoglobulin A vasculitis 16 trials
- Cryoglobulinemic vasculitis 4 trials Sub-types →
- Hypocomplementemic urticarial vasculitis 2 trials
- Cutaneous leukocytoclastic angiitis 1 trial
- Erythema elevatum diutinum 0 trials
-
Hypersensitivity vasculitis 0 trials · 16 incl. sub-types
2 sub-types
- Immunoglobulin A vasculitis 16 trials
- Allergic cutaneous vasculitis 1 trial
-
Kawasaki disease 15 trials
-
Cutaneous vasculitis 4 trials · 5 incl. sub-types
1 sub-type
- Allergic cutaneous vasculitis 1 trial
-
Deficiency of adenosine deaminase 2 3 trials
-
Retinal vasculitis 2 trials
-
Aortitis 1 trial
-
Livedoid vasculopathy 1 trial
-
Choroiditis 0 trials · 1 incl. sub-types
4 sub-types
- Serpiginous choroiditis 1 trial
- Infectious posterior uveitis 0 trials
- Multifocal choroiditis 0 trials Sub-types →
- Paraneoplastic uveitis 0 trials
-
Secondary vasculitis 0 trials · 1 incl. sub-types
2 sub-types
- Drug-induced vasculitis 1 trial
- Postinfectious vasculitis 0 trials
-
Shwartzman phenomenon 0 trials
-
Autoimmune vasculitis 0 trials
1 sub-type
- Rheumatoid vasculitis 0 trials
-
Lymphangitis 0 trials
-
Vasculitis, lymphocytic, nodular 0 trials
Most studied deeper sub-types
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control Stopped earlyThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising vasculitis drug trial halted early
Disease control Stopped earlyThis study compared two drugs, obinutuzumab and rituximab, for treating a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could help more patients achieve remission and clear disease markers. However, the trial…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control Stopped earlyThis study tested whether hydroxychloroquine, a drug used for lupus and arthritis, could help control ANCA vasculitis—a group of autoimmune diseases that cause blood vessel inflammation. Adults with mild disease activity were randomly assigned to receive hydroxychloroquine or a p…
Phase 4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could an arthritis drug tame giant cell arteritis?
Disease control Stopped earlyThis study tested whether adding anakinra, an anti-inflammatory drug, to standard steroid treatment could lower relapse rates in people with giant cell arteritis, a blood vessel disease. The trial planned to include 70 adults over 50 but was stopped early with only 30 participant…
Phase 3 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control Stopped earlyThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Blood test may help some ANCA patients skip unnecessary drugs
Knowledge-focused Stopped earlyThis study looked at whether a specific type of immune cell (CD5+ regulatory B cells) can predict relapse risk in people with ANCA vasculitis, a rare autoimmune disease that damages blood vessels. Researchers aimed to see if patients with normal levels of these cells after initia…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC